Fresh analysis indicates that people who come off new weight-loss injections like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end traditional lifestyle programs.
Published data in a leading medical journal points out that while obese individuals frequently drop substantial amounts of their total mass while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"People purchasing these medications must be informed of the potential of fast rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
That rate of regain means a return to starting weight within about a year and a half.
Weighing Treatments
The research, which looked at dozens of studies involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
Scientists note that individuals who shed pounds through dieting typically experience a more gradual weight regain—approximately 100 grams monthly—once they finish.
Explaining the Quick Regain
Nutrition scientists believe the way of the injections accounts for the accelerated rebound.
The injections copy a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication results in hunger is no longer kept in check, making binge eating far more likely."
A Chronic Issue?
The NHS recommend the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts say that, given the high risk of weight regain, the treatment should be considered long-term.
This view is reinforced by pharmaceutical companies, who state that the results "highlight the persistent nature of obesity," akin to managing conditions like high blood pressure.
Patient Testimonies
Individuals who have stopped the jabs describe a sudden return of cravings.
"I experienced a trigger activating and I was suddenly extremely hungry," described an individual.
This difficulty is worsened if users have not developed lasting dietary or behavioural changes during therapy.
Significant Interest
Figures suggest that a significant number of people in the UK have tried these injections in the past year, with demand remaining high.
- Adoption is greater among females compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, clinicians caution that while GLP-1 drugs are effective tools for weight loss, they are not a standalone fix and maintained weight loss relies on ongoing behavioural support.
